Mounjaro vs Ozempic

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both incretin-based therapies for type 2 diabetes, but they differ in mechanism, brand positioning, approved indications, and clinical efficacy profiles. Understanding these differences is essential for formulary decisions, insurance navigation, and patient counseling.

Brand Names and Formulations

Ozempic (Semaglutide)

Formulation	Indication	Dose Range	Route
Ozempic (injection pen)	Type 2 diabetes	0.25–2 mg weekly	SC
Rybelsus (oral tablet)	Type 2 diabetes	3–14 mg daily	Oral
Wegovy (injection pen)	Obesity/weight management	0.25–2.4 mg weekly	SC

Ozempic is the diabetes-specific brand; Wegovy is the obesity-specific brand. Same molecule, different doses and indications.

Mounjaro (Tirzepatide)

Formulation	Indication	Dose Range	Route
Mounjaro (injection pen)	Type 2 diabetes	2.5–15 mg weekly	SC
Zepbound (injection pen)	Obesity/weight management	2.5–15 mg weekly	SC

Mounjaro is the diabetes brand; Zepbound is the obesity brand. Both use tirzepatide.

Mechanism of Action

Property	Mounjaro (Tirzepatide)	Ozempic (Semaglutide)
Drug class	GIP/GLP-1 dual agonist	GLP-1R selective agonist
Receptors	GIPR + GLP-1R	GLP-1R only
GIPR EC₅₀	~0.14 nM	No agonism
GLP-1R EC₅₀	~0.18 nM	~0.2 nM
Albumin binding	C-20 eicosanedioic acid	C-18 fatty diacid
Half-life	~116 hrs (5 days)	~165 hrs (7 days)

Tirzepatide’s dual agonism produces synergistic effects on insulin secretion, appetite suppression, and weight loss that exceed GLP-1R agonism alone.

Approved Indications

Ozempic

• FDA-approved: Type 2 diabetes (glycemic control)
• Not FDA-approved for obesity: Wegovy is the obesity brand
• Off-label: Often prescribed for weight management (legal but not approved)
• Global approvals: Widely approved in EU, UK, Japan, Australia for T2D

Mounjaro

• FDA-approved: Type 2 diabetes (glycemic control)
• FDA-approved for obesity: Zepbound (same molecule)
• Global approvals: Expanding; approved in EU, UK for T2D
• Insurance: Mounjaro has broader T2D coverage than Zepbound for obesity

Dosing Regimens

Ozempic

Phase	Dose	Duration
Initiation	0.25 mg weekly	4 weeks
Escalation 1	0.5 mg weekly	4+ weeks
Escalation 2	1.0 mg weekly	4+ weeks
Maximum	2.0 mg weekly	Ongoing

Mounjaro

Phase	Dose	Duration
Initiation	2.5 mg weekly	4 weeks
Escalation 1	5.0 mg weekly	4+ weeks
Escalation 2	7.5 mg weekly	4+ weeks
Escalation 3	10.0 mg weekly	4+ weeks
Maximum	15.0 mg weekly	Ongoing

Both agents use 4-week titration intervals. Mounjaro has 5 dose levels; Ozempic has 4 dose levels.

Efficacy Data

HbA1c Reduction

Dose	Mounjaro	Ozempic
Low dose	~1.5% (5 mg)	~1.0% (0.5 mg)
Mid dose	~2.0% (10 mg)	~1.5% (1.0 mg)
Max dose	~2.4–2.6% (15 mg)	~1.8–2.0% (2.0 mg)

Weight Loss (in T2D patients)

Dose	Mounjaro	Ozempic
Low dose	~5–7 kg	~3–4 kg
Mid dose	~7–9 kg	~5–6 kg
Max dose	~10–12 kg	~6–8 kg

SURPASS-2 (Head-to-Head)

The most direct comparison:

• Tirzepatide 15 mg: 2.46% HbA1c reduction, 11.7 kg weight loss
• Semaglutide 1 mg: 1.84% HbA1c reduction, 5.7 kg weight loss
• Note: Semaglutide was dosed at 1 mg, not 2.0 mg

Side Effect Profiles

Both agents share GLP-1R-mediated GI effects:

Side Effect	Mounjaro	Ozempic
Nausea	12–31%	15–20%
Diarrhea	12–17%	8–12%
Vomiting	5–12%	5–9%
Decreased appetite	11–18%	9–15%
Constipation	11–18%	5–10%
Injection site reactions	2–6%	1–7%

Mounjaro generally shows comparable or slightly lower GI side effect rates. Both agents carry boxed warnings for thyroid C-cell tumors (rodent data).

Cost and Insurance Coverage

Ozempic

Factor	Ozempic
List price (monthly)	~$935–1,050
Insurance coverage	Broad (T2D)
Prior authorization	Usually required
Copay with insurance	$25–250/month
GoodRx/coupons	Available (~$800–900)
Oral option	Rybelsus (~$900–1,000)

Mounjaro

Factor	Mounjaro
List price (monthly)	~$1,023–1,059
Insurance coverage	Broad (T2D)
Prior authorization	Usually required
Copay with insurance	$25–250/month
GoodRx/coupons	Available (~$900–1,000)
Oral option	None

Mounjaro has a slightly higher list price, but insurance copays are often comparable. Ozempic has the advantage of an oral formulation (Rybelsus).

Insurance Navigation

T2D Coverage

Both Ozempic and Mounjaro have broad insurance coverage for T2D:

• Step therapy: Most insurers require metformin failure first
• PA requirements: Documentation of T2D diagnosis, HbA1c ≥7.0%, prior medication trial
• Formulary status: Both on most formularies, though placement varies

Obesity Coverage

• Wegovy (semaglutide 2.4 mg): Increasing coverage as plans update policies
• Zepbound (tirzepatide): Newer; coverage expanding but less established
• Ozempic off-label: Sometimes covered for obesity if Wegovy unavailable
• Mounjaro off-label: Not typically covered for obesity (use Zepbound)

When to Choose Which

Ozempic may be preferred when:

• Oral administration is desired (Rybelsus)
• Insurance coverage favors Ozempic/Wegovy
• Longer clinical track record is preferred
• Cost is a primary concern
• Simpler mechanism of action is desired

Mounjaro may be preferred when:

• Greater HbA1c reduction is needed
• More weight loss is desired
• Patient has failed Ozempic or other GLP-1 RAs
• Dual incretin mechanism is of interest
• Insurance coverage is comparable

References

1. Frías JP, et al. “Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).” NEJM 2023;388:523-534.
2. Marso SP, et al. “Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).” NEJM 2016;375:1834-1844.
3. Rosenstock J, et al. “Efficacy and safety of tirzepatide in patients with type 2 diabetes (SURPASS-1).” Lancet 2021;398:143-155.
4. Davies MJ, et al. “Semaglutide 2.4 mg once weekly in adults with overweight or obesity (STEP 2).” Lancet 2021;397:1003-1012.
5. Jastreboff AM, et al. “Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).” NEJM 2022;387:205-216.